Efficacy and Safety Study of Titrated Oral Misoprostol Solution for Labor Augmentation

NCT ID: NCT00695331

Last Updated: 2008-07-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

143 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-02-29

Study Completion Date

2009-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the efficacy and safety of titrated oral misoprostol solution with intravenous oxytocin for labor augmentation in women without adequate uterine contractions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Numerous labor course necessitate augmentation when uterine contractions are inadequate. When the cervix is favorable, labor augmentation attempts are more likely to be successful. Augmentation is these women is traditionally undertaken with intravenous oxytocin and amniotomy, either alone or in combination.

In our previous trial, it has been proven that the method of titrated oral misoprostol is associated with a lower incidence of uterine hyperstimulation and a lower cesarean delivery rate than vaginal misoprostol for labor induction in patients with unfavorable cervix. Because administering Misoprostol solution is easy and cost saving, it is worth to develop this novel method in labor augmentation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Labor

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Labor Augmentation Misoprostol Oxytocin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Titrated Oral Misoprostol Solution

Group Type EXPERIMENTAL

Misoprostol

Intervention Type DRUG

Titrated Misoprostol Solution

2

Intravenous Oxytocin

Group Type ACTIVE_COMPARATOR

Oxytocin

Intervention Type DRUG

Titrated Intravenous Oxytocin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Misoprostol

Titrated Misoprostol Solution

Intervention Type DRUG

Oxytocin

Titrated Intravenous Oxytocin

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cytotec Piton-S

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pregnancy between 36 and 42 weeks of gestation
* Live singleton
* Cephalic presentation
* A reassuring fetal heart rate pattern
* Bishop score greater than 6
* Inadequate uterine contraction (less than or equal to 2 per 10 minutes)

Exclusion Criteria

* Nonreassuring fetal heart rate pattern
* Parity more than five
* Uterine scar
* Suspected placental abruption with abnormal fetal heart rate
* Vaginal bleeding other than "bloody show"
* Significant maternal cardiac, renal, or hepatic disease
* hypersensitivity to oxytocin, misoprostol or prostaglandin analogues
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

China Medical University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

China Medical University Beigang Hospital

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Shi-Yann Cheng, MD

Role: STUDY_CHAIR

China Medical University Beigang Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Labor Unit, Department of Obstetric and Gynecology, China Medical Univertiy Hospital

Taichung, , Taiwan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ming Ho, MD

Role: CONTACT

Phone: 886-4-22062121

Email: [email protected]

Shi-Yann Cheng, MD

Role: CONTACT

Phone: 886-5-7837901

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ming Ho, MD

Role: primary

Shi-Yann Cheng, MD

Role: backup

References

Explore related publications, articles, or registry entries linked to this study.

Cheng SY, Ming H, Lee JC. Titrated oral compared with vaginal misoprostol for labor induction: a randomized controlled trial. Obstet Gynecol. 2008 Jan;111(1):119-25. doi: 10.1097/01.AOG.0000297313.68644.71.

Reference Type BACKGROUND
PMID: 18165400 (View on PubMed)

Ho M, Cheng SY, Li TC. Titrated oral misoprostol solution compared with intravenous oxytocin for labor augmentation: a randomized controlled trial. Obstet Gynecol. 2010 Sep;116(3):612-618. doi: 10.1097/AOG.0b013e3181ed36cc.

Reference Type DERIVED
PMID: 20733443 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.cmuh.org.tw

China Medical University Hospital

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DMR96-IRB-176

Identifier Type: -

Identifier Source: secondary_id

CMUBH R96007

Identifier Type: -

Identifier Source: org_study_id